Literature DB >> 9193761

Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation.

S Oziel-Taieb1, C Faucher-Barbey, C Chabannon, P Ladaique, P Saux, F Gouin, J A Gastaut, D Maraninchi, D Blaise.   

Abstract

A 38-year-old man, blood group A+, was allotransplanted for multiple myeloma from his fully matched sister, blood group O+. Anti-A antibodies IgG and IgM titres of the donor were low. Allogeneic peripheral blood stem cells were harvested by leukapheresis after subcutaneous administration of G-CSF. Rapid engraftment occurred since 5.6 x 10(9)/l leukocytes were achieved on day +9 post-transplant. At this time a severe immune haemolytic syndrome occurred and direct antiglobulin test was positive (IgG and C3d). Elution showed an anti-A specificity. Evolution was rapidly unfavourable related to multiorgan failure. The patient died on day +20 post-transplant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193761     DOI: 10.1038/sj.bmt.1700794

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Authors:  Nandita Khera; Jack Jinneman; Barry E Storer; Shelly Heimfeld; Megan M O'Meara; Thomas R Chauncey; Stephanie J Lee; Michael Linenberger
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-15       Impact factor: 5.742

2.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

Review 3.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion.

Authors:  Z Shu; S Heimfeld; D Gao
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

4.  Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning.

Authors:  Dario Marenchino; Laura Maddalena; Riccardo Balbo; Ilaria Avonto; Giuseppe Menardi; Maristella Prucca; Laura Perotti; Nicola Mordini; Gianmichele Peano
Journal:  Blood Transfus       Date:  2010-05-19       Impact factor: 3.443

5.  ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations.

Authors:  Judith S Hecker; Adam Wahida; Erik Hameister; Aneta Filo; Jürgen Ruland; Florian Bassermann; Martin Hildebrandt; Mareike Verbeek; Hendrik Poeck
Journal:  EJHaem       Date:  2021-03-24

6.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

7.  Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.

Authors:  Hee-Jung Chung; Je-Hwan Lee; Seog-Woon Kwon
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.